Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

The researchers here report on the effects of methylene blue (MB)-based malaria combination therapy on gametocytaemia during a randomised-controlled trial in Burkina Faso.

Who Took Part

The study group was 180 children.

The age groups tagged for this paper are children.

An open-label randomised controlled phase II study in 180 children aged 6-10 years with uncomplicated falciparum malaria was conducted in Nouna, north-western Burkina Faso.

Children were randomised to MB-artesunate (AS), MB-amodiaquine (AQ), and AS-AQ (local standard of care).

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Methylene blue (non-peptide stack partner) study: the children and staff both knew the treatment.

A time span of 28 days appears in the methods.

Overall follow-up was for 28 days, follow-up for gametocytaemia was for 14 days.

What Was Measured

PubMed files the paper under topics including Amodiaquine, Antimalarials, Artemisinins, Artesunate, Burkina Faso, Germ Cells and Malaria, Falciparum.

What This Means in Plain Language

The paper is a randomized and open-label study of Methylene blue (non-peptide stack partner) in 180 children over 28 days.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (PloS one), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.